Filing Details

Accession Number:
0001522767-24-000033
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-29 19:07:34
Reporting Period:
2024-04-27
Accepted Time:
2024-04-29 19:07:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1522767 Marimed Inc. MRMD Medicinal Chemicals & Botanical Products (2833) 274672745
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1866577 Timothy Shaw C/O Marimed Inc.
10 Oceana Way
Norwood, MA 02062
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-04-27 111,111 $0.00 8,588,183 No 4 M Direct
Common Stock Disposition 2024-04-29 40,205 $0.26 8,547,978 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, Par Value $.001 Per Share Restricted Stock Units (RSU) Disposition 2024-04-27 111,111 $0.00 111,111 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
333,334 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,000,000 Indirect By the Shaw Family Trust
Footnotes
  1. RSUs convert to shares of common stock on a one-for-one basis.
  2. Reflects shares of common stock sold pursuant to a Rule 10b5-1 instruction letter previously adopted by the Reporting Person on March 14, 2023 to satisfy tax withholding obligations in connection with the vesting of RSUs.
  3. The reporting person's spouse is the trustee of the trust and the shares held in the trust are for the benefit of the reporting person's children. The trust is an irrevocable trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  4. The RSUs vest over a three-year period in equal one-sixth installments every six months following the October 27, 2022 grant date, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.